Galectin Therapeutics (GALT) Change in Accured Expenses (2010 - 2026)

Galectin Therapeutics' Change in Accured Expenses history runs 17 years deep, the most recent figure standing at $1.8 million for Q1 2026.

• In Q1 2026, Change in Accured Expenses rose 450.77% year-over-year to $1.8 million; the TTM figure through Mar 2026 stood at $8.6 million (up 179.28% YoY), while the FY2025 annual figure was $6.2 million, up 40.43% from the prior year.
• Change in Accured Expenses for Q1 2026 stood at $1.8 million, down from $9.8 million in the prior quarter.
• The five-year high for Change in Accured Expenses was $9.8 million in Q4 2025, with the low at -$3.4 million in Q3 2024.
• The 5-year median for Change in Accured Expenses is $843000.0 (2024), against an average of $1.1 million.
• The sharpest annual moves came in 2022 and 2023: Change in Accured Expenses surged 4778.05% in 2022, then sank 1033.33% in 2023.
• Galectin Therapeutics' Change in Accured Expenses stood at $3.3 million in 2022, then soared by 51.78% to $5.1 million in 2023, then climbed by 18.04% to $6.0 million in 2024, then surged by 63.84% to $9.8 million in 2025, then plunged by 81.35% to $1.8 million in 2026.
• Business Quant data shows GALT's Change in Accured Expenses at $1.8 million in Q1 2026, $9.8 million in Q4 2025, and -$345000.0 in Q3 2025.